Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Low Erythropoietin to Albumin Ratio in the Serum Predicts Less Reversibility of Renal Impairment with Poorer Prognosis in Multiple Myeloma

Kai Sun, Ying Liu, Yanliang Bai, Haoyan Wang, Mengzhen Wang, Yuan Chen, Li Bao

Blood (2023) 142 (Supplement 1): 6681.

https://doi.org/10.1182/blood-2023-182670

Published: 2023

Journal Articles

Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

Li Bao, Kai HU, Xiaoyan Ke, Yutong Wang, Mengzhen Wang, Lei Shi, Kai Sun

Blood (2023) 142 (Supplement 1): 6095.

https://doi.org/10.1182/blood-2023-181041

Published: 2023

Journal Articles

Combination of Circulating Plasma Cells Enhances the Efficacy of R2-ISS Stage System for Risk Stratification of Newly Diagnosed Multiple Myeloma: A Single-Center Real-World Study

Bin Chu, Yutong Wang, Lei Shi, Kai Sun, Li Bao

Blood (2023) 142 (Supplement 1): 4740.

https://doi.org/10.1182/blood-2023-181006

Published: 2023

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2022) 140 (Supplement 1): 10167–10169.

https://doi.org/10.1182/blood-2022-159361

Published: 2022

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2022) 140 (Supplement 1): 12637–12639.

https://doi.org/10.1182/blood-2022-169057

Published: 2022

Journal Articles

Validation of the Impede VTE Score for Prediction of Venous Thromboembolism in Chinese Patients with Multiple Myeloma: A Retrospective Cohort Study

Li Bao, Yu-Tong Wang, Min-qiu Lu, Junling Zhuang, Bin Chu, Lei Shi, Shan Gao, Li-juan Fang, Qiu-qing Xiang, Xi Liu, Yue-hua Ding, Kai Sun

Blood (2022) 140 (Supplement 1): 5146–5147.

https://doi.org/10.1182/blood-2022-168633

Published: 2022

Journal Articles

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Li Bao, Min-qiu Lu, Peng Liu, Yu-Tong Wang, Junling Zhuang, Mei Zhang, Zhongjun Xia, Zhenling Li, Ying Yang, Zhenyu Yan, Hongmei Jing, Wenming Chen, Hebing Zhou, Rong Fu, Yuping Gong, Wenrong Huang, Yongqing Zhang

Blood (2022) 140 (Supplement 1): 12564–12565.

https://doi.org/10.1182/blood-2022-168068

Published: 2022

Journal Articles

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Zhe Zhuang, Lei Shi, Ying Tian, Dongmei Zou, Ru Feng, Fei Dong, Yanping Ma, Hong Yu, Wei-wei Tian, Shuangjiao Liu, Liangming Ma, Rong Fu, Hongmei Jing, Hui Liu, Wanling Sun, Chen Wenming, Yin Wu, Li Bao, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2021-149502

Published: 2021

Journal Articles

Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients

Miao Chen, Li Bao, Wenming Chen, Rong Fu, Rong Guo, Hongmei Jing, Hui Liu, Qinhua Liu, Yanping Ma, Xiuli SUN, Wei Wang, Yafei Wang, Xiaojing Yan, Jiang Qian, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4783.

https://doi.org/10.1182/blood-2021-148237

Published: 2021

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2021) 138 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2021-152542

Published: 2021

Journal Articles

Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study

Aijun Liu, Rong Fu, PhD, Zunmin Zhu, Li Bao, MD, Huizheng Bao, Da Gao, MD, Yanping Ma, PhD, Chen Wenming, MD, Hong Yu

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139064

Published: 2020

Journal Articles

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Blood (2019) 134 (Supplement_1): 5493.

https://doi.org/10.1182/blood-2019-125447

Published: 2019

Journal Articles

The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China

Blood (2019) 134 (Supplement_1): 5592.

https://doi.org/10.1182/blood-2019-130040

Published: 2019

Journal Articles

Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China

Blood (2019) 134 (Supplement_1): 3181.

https://doi.org/10.1182/blood-2019-128614

Published: 2019

Journal Articles

Reversibility of Renal Insufficiency in Patients with Newly Diagnosed Multiple Myeloma and the Role of different induction Regimens

Li Bao, Jin Lu, MD, Xiaojun Huang

Blood (2014) 124 (21): 5749.

https://doi.org/10.1182/blood.V124.21.5749.5749

Published: 2014

Journal Articles

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

Blood (2013) 121 (20): 4056–4062.

https://doi.org/10.1182/blood-2012-11-468348

Published: 2013

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Fludarabine Combined with Cytarabine in the Treatment of Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).

Bin Jiang, Wei Wang, Li Bao, Xiaojun Huang, Jin Lu, Debing Wang, Daopei Lu

Blood (2005) 106 (11): 4593.

https://doi.org/10.1182/blood.V106.11.4593.4593

Published: 2005

NARROW

Low Erythropoietin to Albumin Ratio in the Serum Predicts Less Reversibility of Renal Impairment with Poorer Prognosis in Multiple Myeloma

Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

Combination of Circulating Plasma Cells Enhances the Efficacy of R2-ISS Stage System for Risk Stratification of Newly Diagnosed Multiple Myeloma: A Single-Center Real-World Study

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Validation of the Impede VTE Score for Prediction of Venous Thromboembolism in Chinese Patients with Multiple Myeloma: A Retrospective Cohort Study

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China

Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China

Reversibility of Renal Insufficiency in Patients with Newly Diagnosed Multiple Myeloma and the Role of different induction Regimens

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

Efficacy and Safety of Fludarabine Combined with Cytarabine in the Treatment of Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only